A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis (LUMINATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00404885
Recruitment Status : Completed
First Posted : November 29, 2006
Last Update Posted : June 22, 2012
Information provided by (Responsible Party):
Lux Biosciences, Inc.

Brief Summary:
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis

Condition or disease Intervention/treatment Phase
Uveitis, Anterior Panuveitis Drug: Placebo Drug: LX211 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis
Study Start Date : January 2007
Actual Primary Completion Date : November 2008
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Placebo
Active Comparator: LX211, 0.2 mg/kg Drug: LX211
0.2 mg/kg, twice a day (BID)
Active Comparator: LX211, 0.4 mg/kg Drug: LX211
0.4 mg/kg, twice a day (BID)
Active Comparator: LX211, 0.6 mg/kg Drug: LX211
0.6 mg/kg, twice a day (BID)

Primary Outcome Measures :
  1. anterior chamber cells [ Time Frame: 16 and 24 weeks ]

Secondary Outcome Measures :
  1. BCVA [ Time Frame: 24 weeks ]
  2. macular thickness [ Time Frame: 16 and 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   13 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented history of non-infectious anterior, anterior and intermediate- or panuveitis
  • Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy due to the development of an ocular hypertensive response or subjects for whom oral corticosteroid is contraindicated.
  • Grade of 2+ or higher for anterior chamber cells at time of enrollment
  • Considered by the investigator to require corticosteroid-sparing therapy.
  • Subjects not planning to undergo elective ocular surgery during the study

Exclusion Criteria:

  • Uveitis of infectious etiology
  • Presence of an ocular toxoplasmosis scar
  • An immune suppression regimen that includes an alkylating agent within the previous 90 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00404885

  Hide Study Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States
United States, Arizona
Retinal Consultants of Arizona
Phoenix, Arizona, United States, 85014
United States, Illinois
University of Illinois - Chicago
Chicago, Illinois, United States, 60612
United States, Maryland
Wilmer Eye Institute
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
Massachusetts Eye Research and Surgery Institute
Cambridge, Massachusetts, United States, 02142
United States, Michigan
Associated Retinal Consultants, PC
Grand Rapids, Michigan, United States, 49546
United States, Missouri
Tauber Eye Center
Kansas City, Missouri, United States, 64111
United States, New York
New York Eye & Ear Hospital
New York, New York, United States, 10003
United States, North Carolina
Duke University Eye Center, Erwin Road
Durham, North Carolina, United States
United States, Oregon
Oregon Health Sciences University
Portland, Oregon, United States, 97201
United States, Texas
Brian B. Berger, MD, P.A.
Austin, Texas, United States, 78705
Retina & Uveitis Consultants of Texas
San Antonio, Texas, United States, 78240
United States, Virginia
Viginia Eye Consultants
Norfolk, Virginia, United States, 23502
Universitätsklinik für Augenheilkunde
Salzburg, Austria
Klinik für Augenheilkunde, Dept. of Ophthalmology
Wien, Austria
Canada, Quebec
McGill University Health Center
Montreal, Quebec, Canada, H3A 1A1
Hôpital Pitié Salpétrière, Service d'Ophtalmologie
Paris, France
Universitätsklinikum Freiburg
Freiburg, Germany
Augenklinik der Universität Heidelberg
Heidelberg, Germany
St. Franziskus-Hospital
Münster, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
L V Prasad Eye Institute
Hyderabaad, Andhra Pradesh, India
Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology
Madurai, Tamil Nadu, India
Vittala International Institute of Ophthalmology
Bangalore, India
Advanced Eye Centre, Postgraduate Institute of Medical Education and Research (PGIMER)
Chandigarh, India
Aravind Eye Hospital, Uvea Clinic
Coimbatore, India
Aditya Jyot Eye Hospital Pvt Ltd
Mumbai, India
United Kingdom
Bristol Eye Hospital and University of Bristol
Bristol, United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
Sponsors and Collaborators
Lux Biosciences, Inc.
Study Chair: Eddy Anglade, M.D. Chief Medical Officer

Additional Information:
Responsible Party: Lux Biosciences, Inc. Identifier: NCT00404885     History of Changes
Other Study ID Numbers: LX211-03-UV
EudraCT No: 2006-006545-13
First Posted: November 29, 2006    Key Record Dates
Last Update Posted: June 22, 2012
Last Verified: June 2012

Keywords provided by Lux Biosciences, Inc.:

Additional relevant MeSH terms:
Uveitis, Anterior
Uveal Diseases
Eye Diseases
Iris Diseases